CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.
March 14th 2024
Here is a run-down of some topics we covered in the Spring 2024 issue of CURE.
FDA Approves Dosing Reduction of Tecvayli in Relapsed, Refractory Myeloma
February 21st 2024The Food and Drug Administration has approved a reduced dosing frequency of Tecvayli for patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for at least six months.
Patrick Dempsey Reflects on His Nonprofit, ‘General Hospital’ Star Talks Cancer and More
November 10th 2023From actor Patrick Dempsey saying that his late mother would be proud of his work at The Dempsey Center to a “General Hospital” actor discussing his cancer treatments, here’s what’s happening in the oncology space this week.
Survival May Not Differ by Race in Multiple Myeloma Treated With Abecma
November 6th 2023Researchers have found that, among patients with relapsed/refractory multiple myeloma who received treatment with the CAR-T cell therapy Abecma, race and ethnicity played roles in safety and response but not survival.
Patients With Newly Diagnosed, High-Risk Myeloma See High MRD Negative Rates With Isa-KRd
October 1st 2023Treatment with the combination of Sarclisa, Kyprolis, Revlimid and Isa-KRd generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.